{
}
UBS has maintained a 'Sell' rating for AstraZeneca, setting a target price of 11,300 pence ahead of the company's quarterly results. Analyst Matthew Weston noted that his forecasts align closely with consensus estimates.
UBS has maintained a 'Sell' rating for AstraZeneca, setting a target price of 11,300 pence ahead of the company's quarterly results. Analyst Matthew Weston noted that the forecasts align closely with consensus estimates.
Rallybio, a biotech company focused on rare diseases, faces significant challenges in securing funding for its lead candidate addressing fetal and neonatal alloimmune thrombocytopenia. Co-founders Steve Uden and Martin Mackay, both former Alexion leaders, emphasize the importance of storytelling in attracting investment, despite the tough market conditions. They remain committed to innovation in rare diseases, believing that the medical need will ultimately drive financial support.
Novo Nordisk is poised to report its third-quarter earnings, with analysts optimistic about the stock, reflected in six "buy" and five "hold" ratings. The average price target is set at 963.36 Danish krone, approximately 28% above recent levels, driven by anticipated sales growth of its weight-loss drugs, Ozempic and Wegovy. However, increased competition in the weight-loss market could pose challenges, despite analysts noting the company's strong production advantages.
UBS has maintained a 'Sell' rating for Astrazeneca, setting a target price of 11,300 pence. Analyst Matthew Weston cautioned that preliminary data on weight loss from the oral drug GLP-1 AZD5004 should not lead to definitive conclusions regarding its effectiveness in overweight patients.
UBS has maintained a 'Sell' rating for AstraZeneca, setting a target price of 11,300 pence. Analyst Matthew Weston cautioned that preliminary data on the oral GLP-1 AZD5004 for weight loss should not lead to definitive conclusions regarding its effectiveness in overweight patients.
AstraZeneca Plc reported that its experimental obesity pill is well-tolerated among patients with type-2 diabetes, showcasing data from multiple studies at the ObesityWeek conference in San Antonio, Texas. The oral GLP-1 treatment led to an average weight loss of 5.8% over four weeks, although there was a noted increase in nausea and vomiting related to dosage, as explained by Sharon Barr, executive vice-president of biopharmaceuticals R&D.
The intratumor cancer therapies market, valued at $151.5 million in 2022, is projected to grow at a CAGR of 9.9% from 2023 to 2030, driven by advances in immunotherapy and personalized medicine. Monoclonal antibodies are leading the technology segment, while lung cancer remains the primary application area. North America is the dominant market, fueled by rising cancer prevalence and increased awareness of innovative treatment options.
AstraZeneca is under investigation in China, with local president Leon Wang implicated, raising concerns about the company's future in the market. The probe focuses on aggressive sales tactics related to its oncology drugs, including the lung cancer treatment Tagrisso and the immunotherapy Imjudo.
AstraZeneca's China president, Leon Wang, is under investigation by Chinese authorities, causing the company's shares to drop by 5.3%. While the company confirmed Wang is cooperating, it remains unclear if he is in custody. AstraZeneca has a strong presence in China, having invested significantly in the market.
AstraZeneca PLC
Companies
| Symbol | AZN |
| Name | AstraZeneca PLC |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | United Kingdom |
| State | |
| City | Cambridge |
| Zipcode | CB2 0AA |
| Website | http://www.astrazeneca.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains sell rating for astrazeneca with target price of 11300 pence
17:34 05.11.2024
ubs maintains sell rating for astrazeneca with target price of 11300 pence
16:47 05.11.2024
rallybio navigates funding challenges to advance rare disease treatments
14:00 05.11.2024
analysts optimistic on novo nordisk ahead of third quarter earnings report
Danish Krone
United States Dollar
AstraZeneca PLC
Novo Nordisk A/S
Eli Lilly and Company
Viking Therapeutics, Inc.
DNK
Show more
22:16 04.11.2024
ubs maintains sell rating on astrazeneca with target price of 11300 pence
21:58 04.11.2024
ubs maintains sell rating for astrazeneca with target price of 11300 pence
21:11 04.11.2024
AstraZeneca reports promising results for new obesity treatment in diabetes patients
16:00 04.11.2024
growth of intratumor cancer therapies market driven by innovative treatments and technologies
United States Dollar
Eli Lilly and Company
AbbVie Inc.
AstraZeneca PLC
Amgen Inc.
Novartis AG
Merck & Co., Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Bayer AG
USA
Show more
06:23 04.11.2024
AstraZeneca faces investigation over sales tactics in China oncology drugs
09:10 31.10.2024
AstraZeneca China president under investigation shares drop significantly
15:18 30.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
Stock Market Updates
Government Economic Policies
Industry Mergers & Acquisitions
Energy Sector Developments
Funding Rounds & Investments
CEO Changes
AI Applications
Private Equity Deals
Workplace Trends
Emerging Startups
Fintech Startups
AI Innovations
Global Financial Events
Central Bank Actions
Countries:
Companies:
Apple Inc.
Google Inc.
Tesla, Inc.
Amazon.com, Inc.
Microsoft Corporation
Tesmec S.p.A.
Alphabet Inc.
OpenAI ERC USD
Walmart Inc.
SWIGGY LIMITED
TENCENT
NVIDIA Corporation
Foxconn Technology Co., Ltd.
Hollywood Bowl Group PLC
NASDAQ Composite
Wise plc
Mastercard Inc
Bose Corporation
Mistral 1
Fast Retailing Co., Ltd.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
British Pound Sterling
Japanese Yen
United Arab Emirates Dirham
Vietnamese Đồng
South Korean Won
New Zealand Dollar
Saudi Riyal
Thai Baht
Australian Dollar
Indonesian Rupiah
Singapore Dollar
Omani Rial
Bahraini Dinar
Qatari Riyal
Algerian Dinar
Egyptian Pound
People: